Valuation of MammoRisk® Software Announced by PREDILIFE

PREDILIFE, a France-based company known for its application of artificial intelligence in predicting pathological risks, has released the valuation figures for its MammoRisk® software. Conducted by SORGEM Evaluation, the software's estimated value ranges between €191.7 million to €223.3 million with a central value of €207.3 million.

The evaluation of MammoRisk® underlines its importance in the preventive medical tools market, particularly in the breast cancer domain. This software assists in stratified screening and is currently employed in a significant European clinical study, MyPeBS, comparing its efficacy against conventional screening methods.

MammoRisk® has been designed for women over 40, targeting a broader demographic than curative treatments. Breast cancer remains the most common cancer among women globally, creating substantial market potential for this predictive solution. Additionally, the ongoing clinical study across Europe is set to solidify its viability and adoption in standard cancer screening protocols by 2028.